Journal article
Benefit-Risk Assessment of Raloxifene in Postmenopausal Osteoporosis
Abstract
Raloxifene, a nonsteroidal benzothiophene, is a second-generation selective estrogen receptor modulator (SERM) that is an antiresorptive agent. Raloxifene is a non-hormonal agent that binds to the estrogen receptor and results in estrogen agonist effects on bone and the cardiovascular system and estrogen antagonist effects on endometrial and breast tissue. Raloxifene has diverse pharmacodynamic properties due to its differential interactions …
Authors
Cranney A; Adachi JD
Journal
Drug Safety, Vol. 28, No. 8, pp. 721–730
Publisher
Springer Nature
Publication Date
8 2005
DOI
10.2165/00002018-200528080-00006
ISSN
0114-5916